Search results
Results from the Tech24 Deals Content Network
August 8, 2024 at 11:52 AM. Shares of Viatris (NASDAQ: VTRS) were jumping 6% higher as of 11:18 a.m. ET on Thursday after rising as much as 12.4% earlier in the day. The solid gain came after the ...
In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India, [21] and one of the 25 best companies offering career development in Ireland. [22] In May 2023, USA Today included Viatris in its list of 400 US companies that have reduced their greenhouse gas emissions intensity from 2019 to 2021. [23]
Viatris also reaffirmed its full-revenue revenue forecast to the range of $15.5 billion to $16 billion, compared to analysts' estimates of $15.60 billion. Excluding items, the company reported a ...
When it made its debut last November, Viatris (VTRS) was touted as a value-unlocking divestiture. The pharmaceutical company, formed when Pfizer (PFE) merged its Upjohn unit with Mylan NV, started ...
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer 's off-patent medicine division, to form Viatris. [ 1] Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK [ 2] and a "Global Center" in Canonsburg ...
Viatris was formed with the merger of Mylan and Pfizer's Upjohn business and has generic and key branded drugs in its portfolio, including erectile dysfunction drug Viagra, anti-anxiety medication ...
Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?